NCT07171307View on ClinicalTrials.gov

Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Conjunctivitis, Allergic

Trial Locations (1)

06800

Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro, Mexico City

All Listed Sponsors

lead

Instituto de Oftalmología Fundación Conde de Valenciana

OTHER

NCT07171307 - Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy | Biotech Hunter | Biotech Hunter